BRPI0408950A - método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica - Google Patents
método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação diméricaInfo
- Publication number
- BRPI0408950A BRPI0408950A BRPI0408950-2A BRPI0408950A BRPI0408950A BR PI0408950 A BRPI0408950 A BR PI0408950A BR PI0408950 A BRPI0408950 A BR PI0408950A BR PI0408950 A BRPI0408950 A BR PI0408950A
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- determining
- situation
- cancer
- cell surface
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODO PARA DETERMINAR A SITUAçãO DE DOENçA DE UM PACIENTE, E, MéTODO PARA SELECIONAR UM PACIENTE PARA TRATAMENTO DE UM CáNCER COM UM OU MAIS MEDICAMENTOS DE AçãO DIMéRICA". A invenção está direcionada a uma nova classe de biomarcador em amostras de paciente que compreende dímeros de receptores de membrana de superfície celular. Em um aspecto, a invenção inclui um método de determinar a situação de uma doença ou condição saudável correlacionando-se tal condição com as quantidades de um ou mais dímeros de receptores de membrana de superfície celular medidas diretamente em uma amostra do paciente, em particular uma amostra de tecido fixa. Em um outro aspecto, a invenção inclui um método de determinar uma situação de um câncer em um espécime de um indivíduo correlacionando-se medições de quantidades de um ou mais dímeros de receptores de membrana de superfície celular nas células do espécime para tal situação, incluindo a presença ou ausência de um estado pré canceroso, presença ou ausência de um estado canceroso, prognóstico de um câncer ou responsividade ao tratamento. Preferivelmente os métodos da invenção são implementados usando-se conjuntos de compostos de ligação tendo rótulos moleculares liberáveis que são específicos para componentes múltiplos de um ou mais tipos de dímeros receptores. Depois da ligação, os rótulos moleculares são liberados e separados da mistura de ensaio para análise.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45988803P | 2003-04-01 | 2003-04-01 | |
US10/623,057 US7105308B2 (en) | 2002-07-25 | 2003-07-17 | Detecting receptor oligomerization |
US49448203P | 2003-08-11 | 2003-08-11 | |
US50803403P | 2003-10-01 | 2003-10-01 | |
US51294103P | 2003-10-20 | 2003-10-20 | |
US52325803P | 2003-11-18 | 2003-11-18 | |
PCT/US2004/009717 WO2004092353A2 (en) | 2003-04-01 | 2004-03-30 | Surface receptor complexes as biomarkers |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0408950A true BRPI0408950A (pt) | 2006-03-28 |
Family
ID=33136354
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0408961-8A BRPI0408961A (pt) | 2003-04-01 | 2004-03-30 | método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente |
BRPI0408928-6A BRPI0408928A (pt) | 2003-04-01 | 2004-03-30 | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
BRPI0408950-2A BRPI0408950A (pt) | 2003-04-01 | 2004-03-30 | método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0408961-8A BRPI0408961A (pt) | 2003-04-01 | 2004-03-30 | método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente |
BRPI0408928-6A BRPI0408928A (pt) | 2003-04-01 | 2004-03-30 | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
Country Status (6)
Country | Link |
---|---|
EP (3) | EP1613732A4 (pt) |
JP (2) | JP2006523314A (pt) |
AU (3) | AU2004225439A1 (pt) |
BR (3) | BRPI0408961A (pt) |
CA (3) | CA2521106A1 (pt) |
WO (3) | WO2004092353A2 (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
WO2004092353A2 (en) * | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Surface receptor complexes as biomarkers |
JP2007502417A (ja) * | 2003-08-11 | 2007-02-08 | モノグラム バイオサイエンシズ,インコーポレーテッド | 分子複合体の検出および特徴づけ |
EP1681983A4 (en) * | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY |
CA2580937C (en) * | 2004-09-22 | 2016-02-02 | Tripath Imaging, Inc. | Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
WO2007121465A2 (en) * | 2006-04-18 | 2007-10-25 | Wellstat Biologics Corporation | Detection of proteins from circulating neoplastic cells |
JP2010500577A (ja) * | 2006-08-07 | 2010-01-07 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 癌の予後および予測シグナチャーのプロテオミクスパターン |
BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
EP2097754B2 (en) | 2006-11-28 | 2018-01-24 | Daiichi Sankyo Europe GmbH | Activated her3 as a marker for predicting therapeutic efficacy |
WO2008100624A2 (en) | 2007-02-16 | 2008-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
ES2526211T3 (es) * | 2007-07-13 | 2015-01-08 | Nestec S.A. | Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos |
EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2 DIAGNOSTIC METHODS |
CN102016581B (zh) | 2008-02-25 | 2014-07-30 | 雀巢产品技术援助有限公司 | 用抗体阵列选择乳腺癌治疗药物 |
US8168755B2 (en) * | 2008-05-07 | 2012-05-01 | Eutropics Pharmaceuticals, Inc. | Antibodies specific to heterodimers of Bcl-2 family and uses thereof |
UA104868C2 (uk) * | 2008-08-15 | 2014-03-25 | Меррімак Фармасьютікалз, Інк. | Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції |
CA2764386C (en) | 2008-12-01 | 2018-05-01 | Laboratory Corporation Of America Holdings | P95-her2 antibodies and uses thereof |
SG10201408392PA (en) | 2009-01-15 | 2015-01-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
CA2749817A1 (en) * | 2009-01-15 | 2010-07-22 | Laboratory Corporation Of America Holdings | Methods of determining patient response by measurement of her-2 expression |
US20120100538A1 (en) | 2009-03-24 | 2012-04-26 | Biocept, Inc. | Devices and methods of cell capture and analysis |
EP2995953B1 (en) | 2009-03-24 | 2017-11-29 | Biocept, Inc. | Devices and methods of cell capture and analysis |
WO2010132723A1 (en) | 2009-05-14 | 2010-11-18 | Prometheus Laboratories Inc. | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
JP5795311B2 (ja) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
CN102812045B (zh) | 2009-11-13 | 2018-04-13 | 第一三共欧洲有限公司 | 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法 |
DK2544680T3 (en) | 2010-03-11 | 2015-04-27 | Merrimack Pharmaceuticals Inc | USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER |
US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
WO2012135695A2 (en) * | 2011-03-30 | 2012-10-04 | The Uab Research Foundation | Modulation of cellular migration |
KR101851425B1 (ko) * | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
US20150133450A1 (en) | 2012-06-20 | 2015-05-14 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
WO2014081953A1 (en) | 2012-11-21 | 2014-05-30 | Richard David J | Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives |
WO2014165855A1 (en) * | 2013-04-05 | 2014-10-09 | Laboratory Corporation Of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
AU2014269946A1 (en) * | 2013-05-21 | 2015-12-03 | Nestec S.A. | Methods for predicting and improving the survival of colorectal cancer patients |
US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
AU2014342269B2 (en) | 2013-10-30 | 2020-02-27 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
CN107406881B (zh) | 2015-01-12 | 2021-05-25 | 尤特罗皮克斯制药股份有限公司 | 用于指导癌症治疗的内容相关的诊断测试 |
WO2016127220A1 (en) * | 2015-02-13 | 2016-08-18 | The University Of Queensland | Methods for classifying tumors and uses therefor |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
CA3016914C (en) | 2016-03-15 | 2019-08-27 | Laboratory Corporation Of America Holdings | Methods of assessing protein interactions between cells |
JPWO2019098385A1 (ja) * | 2017-11-20 | 2020-12-24 | コニカミノルタ株式会社 | 薬剤評価方法 |
IT201800008274A1 (it) * | 2018-08-31 | 2020-03-02 | Alifax Srl | Metodo immunometrico per analisi cliniche biologiche |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597531A (en) | 1985-10-04 | 1997-01-28 | Immunivest Corporation | Resuspendable coated magnetic particles and stable magnetic particle suspensions |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
WO1994003812A1 (en) | 1992-07-31 | 1994-02-17 | Syntex (U.S.A.) Inc. | Photoactivatable chemiluminescent matrices |
US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
US6037134A (en) * | 1994-03-07 | 2000-03-14 | New York University Medical Center | Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes |
US5693271A (en) | 1994-09-01 | 1997-12-02 | Chase Industries, Inc. | Rotationally molding an insulated plastic molded door with integral hinge |
US5599631A (en) | 1995-03-08 | 1997-02-04 | Eastman Kodak Company | Fluorinated elastomer/fluorinated resin compositions for toner fusing members |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US6095661A (en) | 1998-03-19 | 2000-08-01 | Ppt Vision, Inc. | Method and apparatus for an L.E.D. flashlight |
CA2340598A1 (en) * | 1998-09-08 | 2000-03-16 | Agouron Pharmaceuticals, Inc. | Modifications of the vegf receptor-2 protein and methods of use |
US6627400B1 (en) | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
US6322980B1 (en) | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
US6514700B1 (en) | 1999-04-30 | 2003-02-04 | Aclara Biosciences, Inc. | Nucleic acid detection using degradation of a tagged sequence |
US6673550B2 (en) | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
US6346384B1 (en) | 2000-03-27 | 2002-02-12 | Dade Behring Inc. | Real-time monitoring of PCR using LOCI |
US7537938B2 (en) * | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
US7255999B2 (en) | 2001-05-21 | 2007-08-14 | Monogram Biosciences, Inc. | Methods and compositions for analyzing proteins |
EP1305632B1 (en) | 2000-05-04 | 2011-07-27 | Siemens Healthcare Diagnostics Products GmbH | Methods for detection of multiple analytes |
US6547654B2 (en) | 2000-07-22 | 2003-04-15 | Americo Del Raso | Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander |
WO2002068668A2 (en) * | 2001-02-22 | 2002-09-06 | Immunex Corporation | Compositions and methods for production cell culture |
AU2002316577A1 (en) | 2001-07-09 | 2003-01-29 | Aclara Biosciences, Inc. | Cell-screening assay and composition |
CA2354690A1 (en) | 2001-07-20 | 2001-10-27 | Jan Prinzmetal | Mat |
US6545102B1 (en) * | 2001-09-27 | 2003-04-08 | Lumigen, Inc. | Polymer-supported photosensitizers |
WO2003068808A1 (en) * | 2002-02-13 | 2003-08-21 | Garvan Institute Of Medical Research | Novel protein complexes and uses therefor |
EP1654377A4 (en) * | 2002-03-01 | 2010-03-24 | Roger Williams Hospital | PROCESSES AND COMPOSITIONS RELATED TO THE SHC PROTEIN FOR THE PROGNOSIS OF BREAST, PROSTATE AND EGG CANCER |
KR20040108655A (ko) * | 2002-03-05 | 2004-12-24 | 아클라라 바이오사이언시스 인코퍼레이티드 | 막-결합된 민감제를 사용하는 복합 분석법 |
PT2263691E (pt) * | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
EP1540347B1 (en) | 2002-07-25 | 2009-09-09 | Aclara BioSciences, Inc. | Detecting receptor oligomerization |
WO2004092353A2 (en) * | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Surface receptor complexes as biomarkers |
EP1681983A4 (en) * | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY |
-
2004
- 2004-03-30 WO PCT/US2004/009717 patent/WO2004092353A2/en active Application Filing
- 2004-03-30 EP EP20040758577 patent/EP1613732A4/en not_active Withdrawn
- 2004-03-30 AU AU2004225439A patent/AU2004225439A1/en not_active Abandoned
- 2004-03-30 JP JP2006509479A patent/JP2006523314A/ja active Pending
- 2004-03-30 BR BRPI0408961-8A patent/BRPI0408961A/pt not_active IP Right Cessation
- 2004-03-30 WO PCT/US2004/009805 patent/WO2004087887A2/en active Application Filing
- 2004-03-30 JP JP2006509481A patent/JP2006521821A/ja active Pending
- 2004-03-30 EP EP04759064.1A patent/EP1613205B1/en not_active Expired - Lifetime
- 2004-03-30 WO PCT/US2004/009715 patent/WO2004091384A2/en active Application Filing
- 2004-03-30 EP EP04759065A patent/EP1613961A4/en not_active Withdrawn
- 2004-03-30 AU AU2004230700A patent/AU2004230700A1/en not_active Abandoned
- 2004-03-30 CA CA002521106A patent/CA2521106A1/en not_active Abandoned
- 2004-03-30 BR BRPI0408928-6A patent/BRPI0408928A/pt not_active IP Right Cessation
- 2004-03-30 AU AU2004229348A patent/AU2004229348A1/en not_active Abandoned
- 2004-03-30 CA CA002521077A patent/CA2521077A1/en not_active Abandoned
- 2004-03-30 BR BRPI0408950-2A patent/BRPI0408950A/pt not_active IP Right Cessation
- 2004-03-30 CA CA002521082A patent/CA2521082A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1613205A4 (en) | 2006-11-29 |
CA2521082A1 (en) | 2004-10-28 |
EP1613205A2 (en) | 2006-01-11 |
CA2521106A1 (en) | 2004-10-14 |
EP1613732A2 (en) | 2006-01-11 |
BRPI0408928A (pt) | 2006-09-12 |
AU2004225439A1 (en) | 2004-10-14 |
WO2004087887A2 (en) | 2004-10-14 |
WO2004092353A2 (en) | 2004-10-28 |
EP1613205B1 (en) | 2013-04-24 |
WO2004087887A3 (en) | 2006-06-15 |
JP2006521821A (ja) | 2006-09-28 |
WO2004091384A3 (en) | 2005-12-29 |
AU2004229348A1 (en) | 2004-10-28 |
JP2006523314A (ja) | 2006-10-12 |
CA2521077A1 (en) | 2004-10-28 |
WO2004092353A3 (en) | 2005-03-03 |
EP1613961A2 (en) | 2006-01-11 |
WO2004091384A2 (en) | 2004-10-28 |
AU2004230700A1 (en) | 2004-10-28 |
EP1613961A4 (en) | 2007-03-07 |
EP1613732A4 (en) | 2012-03-14 |
BRPI0408961A (pt) | 2006-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0408950A (pt) | método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica | |
Kazak et al. | Ablation of adipocyte creatine transport impairs thermogenesis and causes diet-induced obesity | |
van Oosterwijk et al. | Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets | |
Ukegawa et al. | Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells | |
Muir | Flax lignansanalytical methods and how they influence our understanding of biological activity | |
Malik et al. | Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM | |
WO2006044748A3 (en) | RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS | |
Roberts et al. | Mechanisms of mechanical overload-induced skeletal muscle hypertrophy: current understanding and future directions | |
Bartsch et al. | Nocturnal urinary 6‐sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age‐matched controls and shows negative correlation with tumor‐size | |
WO2005037071A3 (en) | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy | |
BRPI0413471A (pt) | métodos para detectar um ou mais complexos de proteìnas e para detectar um complexo em uma amostra biológica | |
Ramage et al. | NMDA receptor expression and activity in osteoarthritic human articular chondrocytes | |
Nagano et al. | The inhibitory effect of soybean and soybean isoflavone diets on 2, 4-dinitrofluorobenzene-induced contact hypersensitivity in mice | |
Park et al. | Osteoblast differentiation profiles define sex specific gene expression patterns in craniosynostosis | |
Lee et al. | Raftlin: a new biomarker in human sepsis | |
Beetch et al. | Subtle alterations in DNA methylation patterns in normal cells in response to dietary stilbenoids | |
WO2006044566A3 (en) | Autocrine growth factor receptors and methods | |
Gut et al. | Myocardial dysfunction induced by food restriction is related to calcium cycling and beta-adrenergic system changes | |
Song et al. | Effects of glyceollin I on vascular contraction in rat aorta | |
BR0209172A (pt) | Método de detecção de doenças induzidas por glúten em uma amostra sanguìnea de um indivìduo, e kit teste para uso no método | |
Wiedswang et al. | Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed | |
Donoso et al. | Neuropeptide Y is released from human mammary and radial vascular biopsies and is a functional modulator of sympathetic cotransmission | |
YAMASHITA et al. | Plasminogen activator as a functional marker for estrogen dependence in human breast cancer cells | |
BRPI0418980A (pt) | método e aparelho para analisar fluido amniótico | |
CN110988346A (zh) | 一种辅助诊断肺癌的标记物以及检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |